Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$3.25 ▼ -0.04
(-1.22%)
MKT CAP: $120.8M • VOL: 103.0K
52W L $3 52W H $15
ROARABLE / RQD
D- • 43/100
PIOTROSKI
2 / 9
ARMP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$36.6M | -$42.4M | -$40.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$173.8M | -$18.9M | -$69.0M |
| EBITDA (Normalized) | -$36.2M | -$40.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$25.8M | -$37.6M | -$47.4M |
| Capital Expenditures (CapEx) | $542.0K | $1.9M | — |
| Free Cash Flow (FCF) | -$26.3M | -$39.4M | -$47.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $8.7M | $9.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$218.6M | -$48.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ARMP.